Table 6 Change in EORTC QLQ-C30 scores... | American Society of Hematology

Table 6

Change in EORTC QLQ-C30 scores following treatment with eculizumab

Scale	Mean (SE) change baseline to wk 52*	P†
Global health status	19.7 (2.05)	<.001
Functioning scales
Role	20.4 (2.67)	<.001
Social	17.4 (2.84)	<.001
Cognitive	8.6 (2.26)	<.001
Physical	14.8 (1.63)	<.001
Emotional	15.6 (2.26)	<.001
Symptom scales
Fatigue	−27.5 (2.32)	<.001
Pain	−8.1 (2.61)	<.001
Nausea and vomiting	−2.5 (1.54)	.002
Single-item measures
Dyspnea	−20.7 (2.96)	<.001
Loss of appetite	−7.0 (2.11)	<.001
Insomnia	−11.6 (2.77)	<.001
Diarrhea	−1.8 (1.96)	<.001
Financial difficulties	−0.7 (2.78)	.768
Constipation	0.4 (2.03)	.985

Scale	Mean (SE) change baseline to wk 52*	P†
Global health status	19.7 (2.05)	<.001
Functioning scales
Role	20.4 (2.67)	<.001
Social	17.4 (2.84)	<.001
Cognitive	8.6 (2.26)	<.001
Physical	14.8 (1.63)	<.001
Emotional	15.6 (2.26)	<.001
Symptom scales
Fatigue	−27.5 (2.32)	<.001
Pain	−8.1 (2.61)	<.001
Nausea and vomiting	−2.5 (1.54)	.002
Single-item measures
Dyspnea	−20.7 (2.96)	<.001
Loss of appetite	−7.0 (2.11)	<.001
Insomnia	−11.6 (2.77)	<.001
Diarrhea	−1.8 (1.96)	<.001
Financial difficulties	−0.7 (2.78)	.768
Constipation	0.4 (2.03)	.985

An increase in the score on the scales for global health status and functioning indicates improvement, whereas a decrease in the scores on the symptom scales and single-item measures indicates improvement.

†

Mixed-model analysis based on change from baseline.

[ViewLarge]

This Feature Is Available To Subscribers Only